In vitro models have identified MET Y1230 as a hotspot for secondary resistance mutations in patients with NSCLC who have been treated with type I MET TKIs like capmatinib.6 Type I TKIs bind to MET's active form, whereas Type II MET TKIs bind to MET's inactive form. This evidence concerns the gene MET and non-small cell lung carcinoma.